JOP20190115A1 - مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) - Google Patents

مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)

Info

Publication number
JOP20190115A1
JOP20190115A1 JOP/2019/0115A JOP20190115A JOP20190115A1 JO P20190115 A1 JOP20190115 A1 JO P20190115A1 JO P20190115 A JOP20190115 A JO P20190115A JO P20190115 A1 JOP20190115 A1 JO P20190115A1
Authority
JO
Jordan
Prior art keywords
parp
adp
ribose
polymerase
poly
Prior art date
Application number
JOP/2019/0115A
Other languages
English (en)
Inventor
Taisuke Takahashi
Arthur Kluge
Bharat Lagu
Nan Ji
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of JOP20190115A1 publication Critical patent/JOP20190115A1/ar
Application granted granted Critical
Publication of JOP20190115B1 publication Critical patent/JOP20190115B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلانية مشتملة على مادة حاملة أو مادة مخفِّفة مقبولة صيدلانياً ومركب ممثل بواسطة الصيغة البنائية التالية: ويتعلق الاختراع الحالي بطريقة لعلاج خاضع للعلاج يعاني من مرض يمكن تخفيفه بتثبيط إنزيم بولي (<span dir="LTR">ADP</span>-ريبوز) بوليمراز (<span dir="LTR">PARP</span>). يوفر الطلب الحالي تعريفات للمتغيرات. شكل 1.
JOP/2019/0115A 2016-12-30 2017-12-28 مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) JOP20190115B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440581P 2016-12-30 2016-12-30
PCT/US2017/068636 WO2018125961A1 (en) 2016-12-30 2017-12-28 Poly-adp ribose polymerase (parp) inhibitors

Publications (2)

Publication Number Publication Date
JOP20190115A1 true JOP20190115A1 (ar) 2019-05-20
JOP20190115B1 JOP20190115B1 (ar) 2023-09-17

Family

ID=61007849

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0115A JOP20190115B1 (ar) 2016-12-30 2017-12-28 مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)

Country Status (33)

Country Link
US (2) US11034670B2 (ar)
EP (1) EP3562822B1 (ar)
JP (1) JP7141399B2 (ar)
KR (1) KR102606799B1 (ar)
CN (1) CN110167926B (ar)
AR (1) AR110706A1 (ar)
AU (1) AU2017388376B2 (ar)
CA (1) CA3047137A1 (ar)
CO (1) CO2019007906A2 (ar)
CY (1) CY1124565T1 (ar)
DK (1) DK3562822T3 (ar)
EA (1) EA201991412A1 (ar)
ES (1) ES2875841T3 (ar)
HR (1) HRP20210887T1 (ar)
HU (1) HUE054382T2 (ar)
IL (1) IL267676B (ar)
JO (1) JOP20190115B1 (ar)
LT (1) LT3562822T (ar)
MA (1) MA47165B1 (ar)
MD (1) MD3562822T2 (ar)
MX (1) MX393606B (ar)
MY (1) MY199045A (ar)
PH (1) PH12019501529A1 (ar)
PL (1) PL3562822T3 (ar)
PT (1) PT3562822T (ar)
RS (1) RS61895B1 (ar)
SA (1) SA519401894B1 (ar)
SI (1) SI3562822T1 (ar)
SM (1) SMT202100321T1 (ar)
TW (1) TWI773718B (ar)
UA (1) UA124777C2 (ar)
WO (1) WO2018125961A1 (ar)
ZA (2) ZA201904004B (ar)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392524B (es) * 2015-10-07 2025-03-24 Salk Inst Biological Studies Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
JOP20190115B1 (ar) * 2016-12-30 2023-09-17 Mitobridge Inc مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)
KR102293986B1 (ko) * 2019-10-30 2021-08-26 충남대학교산학협력단 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
AU2022261011A1 (en) * 2021-04-22 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
CN118076585A (zh) * 2021-07-23 2024-05-24 国家医疗保健研究所 革兰氏阴性菌外排泵抑制剂
CN113603630B (zh) * 2021-08-10 2023-06-27 苏州小栗医药科技有限公司 一种4-苯基哌啶盐酸盐的合成方法
CA3267500A1 (en) 2022-09-19 2024-03-28 Basf Se AZOLE PESTICIDE COMPOUNDS
JPWO2024101336A1 (ar) 2022-11-07 2024-05-16
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
WO2024240108A1 (zh) * 2023-05-19 2024-11-28 上海海和药物研究开发股份有限公司 一种芳基脲类parp1抑制剂、其制备方法及用途
CN117024357B (zh) * 2023-07-03 2026-02-24 山东第二医科大学 一种针对brca突变的选择性抑制剂及其用途
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
CN117510404A (zh) * 2023-11-29 2024-02-06 山西永津集团有限公司 一种4-氨基烟酸的制备方法
WO2025111705A1 (en) * 2023-11-30 2025-06-05 Waverley Pharma Inc. Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
CN118084678B (zh) * 2024-03-01 2024-09-06 长沙唯楚医药科技有限公司 一种2-溴-6-氟苯胺的制备方法
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025227032A1 (en) * 2024-04-26 2025-10-30 Remix Therapeutics Inc. Methods for degradation of cyclin k and inhibition of cyclin dependent kinases
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070737A2 (en) 2000-03-20 2001-09-27 Sepracor, Inc. Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
ES2311012T3 (es) 2000-03-27 2009-02-01 ABBOTT GMBH &amp; CO. KG Ligandos del receptor d3 de la dopamina para el tratamiento de la adiccion.
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2005082887A1 (ja) 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. ピリミジン誘導体
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
WO2006003150A1 (en) * 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
JP2009501235A (ja) 2005-07-15 2009-01-15 シェーリング コーポレイション 癌処置において有用なキナゾリン誘導体
WO2007099828A1 (ja) 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
CA2919905C (en) 2013-07-31 2021-08-10 Merck Patent Gmbh Oxoquinazolinyl-butanamide derivatives
RU2016147727A (ru) 2014-05-07 2018-06-08 Мерк Патент Гмбх Гетероциклилбутанамидные производные
CN105924434A (zh) * 2015-02-28 2016-09-07 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
WO2018026371A1 (en) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Dual nav1.2/5ht2a inhibitors for treating cns disorders
JOP20190115B1 (ar) * 2016-12-30 2023-09-17 Mitobridge Inc مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)

Also Published As

Publication number Publication date
TW201834657A (zh) 2018-10-01
EP3562822B1 (en) 2021-03-10
MD3562822T2 (ro) 2021-07-31
CN110167926A (zh) 2019-08-23
MY199045A (en) 2023-10-11
WO2018125961A8 (en) 2019-05-23
SMT202100321T1 (it) 2021-07-12
US20200071299A1 (en) 2020-03-05
ES2875841T3 (es) 2021-11-11
CA3047137A1 (en) 2018-07-05
US20220033380A1 (en) 2022-02-03
CY1124565T1 (el) 2022-07-22
JP2020512298A (ja) 2020-04-23
PL3562822T3 (pl) 2021-09-13
HRP20210887T1 (hr) 2021-07-23
ZA202003310B (en) 2021-08-25
PT3562822T (pt) 2021-06-02
MX393606B (es) 2025-03-19
NZ754385A (en) 2024-07-05
WO2018125961A1 (en) 2018-07-05
UA124777C2 (uk) 2021-11-17
PH12019501529A1 (en) 2020-09-14
RS61895B1 (sr) 2021-06-30
AR110706A1 (es) 2019-04-24
TWI773718B (zh) 2022-08-11
KR20190098760A (ko) 2019-08-22
CN110167926B (zh) 2022-09-13
JP7141399B2 (ja) 2022-09-22
BR112019011676A2 (pt) 2019-10-15
EA201991412A1 (ru) 2019-11-29
JOP20190115B1 (ar) 2023-09-17
US11034670B2 (en) 2021-06-15
KR102606799B1 (ko) 2023-11-28
HUE054382T2 (hu) 2021-09-28
DK3562822T3 (en) 2021-05-03
IL267676B (en) 2021-09-30
EP3562822A1 (en) 2019-11-06
MA47165B1 (fr) 2021-06-30
AU2017388376A1 (en) 2019-07-04
LT3562822T (lt) 2021-06-10
SI3562822T1 (sl) 2021-08-31
MA47165A (fr) 2019-11-06
US11993585B2 (en) 2024-05-28
AU2017388376B2 (en) 2022-01-06
SA519401894B1 (ar) 2023-02-19
IL267676A (en) 2019-08-29
ZA201904004B (en) 2022-12-21
CO2019007906A2 (es) 2019-10-21
MX2019007870A (es) 2019-08-16

Similar Documents

Publication Publication Date Title
PH12019501529A1 (en) Poly-adp ribose polymerase (parp) inhibitors
NI201800093A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
MX374439B (es) Compuesto de piridona como inhibidor de c-met
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
ZA201701299B (en) Glycosidase inhibitors
EA201690094A1 (ru) Ингибиторы syk
MX2018010192A (es) Inhibidores de glucosidasa.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
AR099376A1 (es) Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
NZ746906A (en) Oxaborole esters and uses thereof
EA201690763A1 (ru) Лечение рака поджелудочной железы
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor